top of page
Our Development Pipeline

TMB-003
Topical Sitaxentan
Timber is in the preclinical stages of evaluating TMB-003 (sitaxsentan), a topical ET-A receptor antagonist for the treatment of sclerotic skin diseases. Timber expects to submit an Investigational New Drug (IND) application in 2022.

If you are interested in any of Timber’s ongoing clinical research programs, please contact trials@timberpharma.com.
bottom of page